Reports Q2 revenue $394.1M, consensus $382.15M. “We delivered another strong quarter as we continued to maximize the value of our commercial portfolio,” said Brian Markison, Chief Executive Officer of Lantheus. “With the strength of our balance sheet and radiopharmaceutical expertise, we also announced three strategic transactions that underscore our ongoing commitment to expand our pipeline of radiodiagnostics and radiotherapeutics to address unmet medical needs for significant patient populations. Looking ahead, we will continue to sustain an attractive financial profile by driving strong performance from our commercial products, advancing our R&D pipeline and executing strategically impactful business development.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LNTH:
- Is LNTH a Buy, Before Earnings?
- Lantheus price target raised to $146 from $105 at B. Riley
- Lantheus price target raised to $137 from $128 at JonesResearch
- Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time
- Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease